Freestone Capital Holdings LLC Has $3.41 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Freestone Capital Holdings LLC lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 45.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 128,629 shares of the biopharmaceutical company's stock after selling 105,582 shares during the period. Freestone Capital Holdings LLC's holdings in Pfizer were worth $3,413,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter worth $26,000. Gladius Capital Management LP boosted its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter valued at $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter valued at $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the third quarter valued at $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Trading Up 0.7 %

Pfizer stock opened at $25.93 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business's 50-day simple moving average is $26.31 and its 200-day simple moving average is $27.27. The firm has a market capitalization of $146.93 billion, a PE ratio of 18.39, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.63%. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer's payout ratio is currently 121.99%.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Guggenheim reissued a "buy" rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 price objective for the company. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.